Latest Conference Articles

Mia Woodward, MD, discusses her study examining the the inclusion of women and minorities in National Eye Institute clincal trials.

Investigators examined both basal and reflex tears from patients with and without Parkinson disease, in search of a potential biomarker.

Investigator Lim sees hope that the EyeArt AI system will be able to screen more patients for diabetic retinopathy and help prevent blindness.

It’s difficult to diagnose Parkinson disease before some permanent neurological damage occurs. But tears may hold the key to earlier diagnoses.

Investigators found that children who experienced concussion-related visual dysfunction had a recovery time nearly twice that of those who did not.

William Freeman, MD, of UCSD and Shiley Eye Institute, discusses the importance of creating treatments for eye diseases that make compliance easier for patients.

William Freeman, MD, discusses the results of a study he led and other potential treatments for geographic atrophy from a session he hosted at ARVO 2019.

Pinakin Davey, DO, PhD, sat down with MD Magazine® at ARVO 2019 to discuss a study he led testing a handheld tonometer for testing IOP.

The artificial intelligence system, EyeArt, was able to detect diabetic retinopathy with a sensitivity of 95.5% and specificity of 86%.

Jonathan Myers, MD, of the Wills Eye Hospital, discusses a study examining the rate of car accidents among glaucoma patients.

After training the EyeArt system on thousands of images of eyes with diabetic retinopathy, investigators tested the AI in a clinical trial.

With 8.5% of the global population having diabetes, there is a growing unmet need for diabetic retinopathy screening. Artificial intelligence may help close the gap.

Aflibercept not only significantly improved patients’ DRSS scores, but it also reduced vision-threatening complications by 75% compared to placebo.

The trial examined 2 doses of aflibercept versus sham in patients with good visual acuity and no center-involving diabetic macular edema.

Investigators reported improvements in BCVA and in central subfield thickness, but noted decreases in superficial and deep capillary density.

A recent study found that early intervention before vision loss does little for patients compared to those who do not receive preemptive treatment.

PANORAMA is the first prospective study of high-risk patients with non-proliferative diabetic retinopathy, but not DME, in the anti-VEGF era.

After analyzing information from a cohort of more than 380,000, investigators found an association between chronic illnesses and visual impairment.

Approximately half of all patients with diabetes suffer from keratopathy, yet diagnoses are still underwhelming. Annual screenings need to become more standard.

Jason Hsu, MD, and his colleagues at the Wills Eye Hospital presented a study at ARVO 2019 regarding short-term outcomes of patients, with nAMD, who switched from afliberecept to ranibizumab.

Mia Woodward, MD, discusses the future of telehealth in ophthalmology and the biggest issues that need to be corrected going forward.

An assessment of the world's largest twin registry found telling patterns of common autoimmune diseases including type 1 diabetes.

No significant differences in cardiovascular outcomes among patients receiving different GLP-1 agonists including exenatide extended-release, exenatide immediate-release, liraglutide, albiglutide, and dulaglutide.

Over the course of 16 weeks, OSA patients receiving CPAP treatment lost 5.7 pounds more on average than patients not receving CPAP therapy.

How the PIONEER-HF and PARADIGM-HF trials have focused on varied, but realistic heart failure patients.

A year-long outpatient care study showed that patients with type 2 diabetes and comorbid cardiovascular disease are 5 times as likely to visit a cardiologist.

A new Puerto Rico-based trial shows that patients on add-on SGLT-2 inhibitors reported greater HbA1C reductions.

It's been 4 years since the drug class reached the market. Are patients adhering to the therapy, and what more potential does it have?

What researchers from the low-risk TAVR trial anticipate they will find in their decade-long assessment.

With cardiovascular drug classes inhibitors owning discussion, how will recent or upcoming guideline updates address their use alongside lifestyle management?